Investors are betting big on Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.
Leonard S. Schleifer
|Revenues ($M) (Past 12 Months)||$5,236|
|Profits ($M) (Past 12 Months)||$1,155|
|Market Value as of Oct. 9, 2017 ($M)||$50,054|